Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. Ba058
2. Tymlos
1. Tymlos
2. Ba058
3. Unii-avk0i6hy2u
4. Bim-44058
5. Abaloparatide [usan:inn]
6. Abaloparatide-sc
7. Avk0i6hy2u
8. Chembl4084894
9. Bdbm50246337
10. C2.29-methyl(22-l-glutamic Acid(f>e),23-l-leucine(f>l),25-l-glutamic Acid(h>e),26-l-lysine(h>k),28-l-leucine(i>l),30-l-lysine(e>k),31-l-leucine(i>l))human Parathyroid Hormone-related Protein-(1-34)-proteinamide
Molecular Weight | 3961 g/mol |
---|---|
Molecular Formula | C174H300N56O49 |
XLogP3 | -20.9 |
Hydrogen Bond Donor Count | 61 |
Hydrogen Bond Acceptor Count | 60 |
Rotatable Bond Count | 145 |
Exact Mass | 3959.2738250 g/mol |
Monoisotopic Mass | 3958.2704702 g/mol |
Topological Polar Surface Area | 1740 Ų |
Heavy Atom Count | 279 |
Formal Charge | 0 |
Complexity | 9310 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 34 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Bone Density Conservation Agents
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)
GDUFA
DMF Review : Complete
Rev. Date : 2024-01-08
Pay. Date : 2023-12-08
DMF Number : 39223
Submission : 2023-11-30
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2022-05-16
Pay. Date : 2022-05-06
DMF Number : 34697
Submission : 2020-05-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36475
Submission : 2021-12-03
Status : Active
Type : II
Details:
Theramex will commercialise and distribute Eladynos (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures on an exclusive basis in the European Economic Area, UK , Australia and Brazil.
Lead Product(s): Abaloparatide Acetate
Therapeutic Area: Musculoskeletal Brand Name: Eladynos
Study Phase: ApprovedProduct Type: Peptide
Sponsor: Theramex
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 20, 2023
Lead Product(s) : Abaloparatide Acetate
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Theramex
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Theramex will commercialise and distribute Eladynos (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures on an exclusive basis in the European Economic Area, UK , A...
Brand Name : Eladynos
Molecule Type : Peptide
Upfront Cash : Undisclosed
March 20, 2023
Details:
Radius’ lead product, TYMLOS® (abaloparatide) was launched in the U.S. in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Lead Product(s): Abaloparatide Acetate
Therapeutic Area: Musculoskeletal Brand Name: Tymlos
Study Phase: ApprovedProduct Type: Peptide
Sponsor: Gurnet Point Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 15, 2022
Lead Product(s) : Abaloparatide Acetate
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Gurnet Point Capital
Deal Size : Undisclosed
Deal Type : Acquisition
Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.
Details : Radius’ lead product, TYMLOS® (abaloparatide) was launched in the U.S. in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Brand Name : Tymlos
Molecule Type : Peptide
Upfront Cash : Undisclosed
August 15, 2022
Details:
The acquisition of Radius by Gurnet Point and Patient Square provides our shareholders with attractive, immediate value at a compelling premium, in addition to the potential future upside of TYMLOS (abaloparatide) through the CVR.
Lead Product(s): Abaloparatide Acetate
Therapeutic Area: Musculoskeletal Brand Name: Tymlos
Study Phase: ApprovedProduct Type: Peptide
Sponsor: Gurnet Point Capital
Deal Size: $890.0 million Upfront Cash: $547.0 million
Deal Type: Acquisition August 15, 2022
Lead Product(s) : Abaloparatide Acetate
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Gurnet Point Capital
Deal Size : $890.0 million
Deal Type : Acquisition
Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.
Details : The acquisition of Radius by Gurnet Point and Patient Square provides our shareholders with attractive, immediate value at a compelling premium, in addition to the potential future upside of TYMLOS (abaloparatide) through the CVR.
Brand Name : Tymlos
Molecule Type : Peptide
Upfront Cash : $547.0 million
August 15, 2022
Details:
The acquisition of Radius by Gurnet Point and Patient Square provides our shareholders with attractive, immediate value at a compelling premium, in addition to the potential future upside of TYMLOS (abaloparatide) through the CVR.
Lead Product(s): Abaloparatide Acetate
Therapeutic Area: Musculoskeletal Brand Name: Tymlos
Study Phase: ApprovedProduct Type: Peptide
Sponsor: Gurnet Point Capital
Deal Size: $890.0 million Upfront Cash: $547.0 million
Deal Type: Acquisition June 23, 2022
Lead Product(s) : Abaloparatide Acetate
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Gurnet Point Capital
Deal Size : $890.0 million
Deal Type : Acquisition
Details : The acquisition of Radius by Gurnet Point and Patient Square provides our shareholders with attractive, immediate value at a compelling premium, in addition to the potential future upside of TYMLOS (abaloparatide) through the CVR.
Brand Name : Tymlos
Molecule Type : Peptide
Upfront Cash : $547.0 million
June 23, 2022
Details:
The data for spine BMD vs. baseline showed abalo-TDS had a 7.1% increase vs. TYMLOS (abaloparatide) +10.9%, both considered clinically meaningful. Despite missing the non-inferiority margin, the transdermal system demonstrated a bone building benefit to patients.
Lead Product(s): Abaloparatide Acetate
Therapeutic Area: Musculoskeletal Brand Name: Tymlos
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Lead Product(s) : Abaloparatide Acetate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Radius Health Update on Abaloparatide Transdermal System
Details : The data for spine BMD vs. baseline showed abalo-TDS had a 7.1% increase vs. TYMLOS (abaloparatide) +10.9%, both considered clinically meaningful. Despite missing the non-inferiority margin, the transdermal system demonstrated a bone building benefit to ...
Brand Name : Tymlos
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 01, 2022
Details:
Company announced phase 3 topline results from the wearABLe study did not meet its primary endpoint evaluating the NI of BA058 (abaloparatide) in postmenopausal women with osteoporosis.
Lead Product(s): Abaloparatide Acetate
Therapeutic Area: Musculoskeletal Brand Name: BA058
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2021
Lead Product(s) : Abaloparatide Acetate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Company announced phase 3 topline results from the wearABLe study did not meet its primary endpoint evaluating the NI of BA058 (abaloparatide) in postmenopausal women with osteoporosis.
Brand Name : BA058
Molecule Type : Peptide
Upfront Cash : Not Applicable
December 08, 2021
Details:
Endo obtained the rights to abaloparatide-subcutaneous injection and abaloparatide-transdermal patch, a novel formulation and route of administration currently undergoing clinical development. Endo, will be responsible for all commercial activities related to abaloparatide.
Lead Product(s): Abaloparatide Acetate
Therapeutic Area: Musculoskeletal Brand Name: BA058
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Endo International
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 05, 2021
Lead Product(s) : Abaloparatide Acetate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Endo International
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada
Details : Endo obtained the rights to abaloparatide-subcutaneous injection and abaloparatide-transdermal patch, a novel formulation and route of administration currently undergoing clinical development. Endo, will be responsible for all commercial activities relat...
Brand Name : BA058
Molecule Type : Peptide
Upfront Cash : Undisclosed
January 05, 2021
Details:
The study was designed to look at the effects on bone mineral density of abaloparatide delivered via a novel transdermal device (“abaloparatide-patch”) compared with the current subcutaneous formulation, marketed as TYMLOS®.
Lead Product(s): Abaloparatide Acetate
Therapeutic Area: Musculoskeletal Brand Name: BA058
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Lead Product(s) : Abaloparatide Acetate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Radius Health: Enrollment Completed for Phase 3 wearABLe Trial
Details : The study was designed to look at the effects on bone mineral density of abaloparatide delivered via a novel transdermal device (“abaloparatide-patch”) compared with the current subcutaneous formulation, marketed as TYMLOS®.
Brand Name : BA058
Molecule Type : Peptide
Upfront Cash : Not Applicable
September 08, 2020
Global Sales Information
Company :
Abaloparatide
Drug Cost (USD) : 156,712,784
Year : 2022
Prescribers : 11168
Prescriptions : 60207
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Abaloparatide
Drug Cost (USD) : 137,835,466
Year : 2021
Prescribers : 11638
Prescriptions : 58817
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Abaloparatide
Drug Cost (USD) : 109,841,019
Year : 2019
Prescribers : 11125
Prescriptions : 53463
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Abaloparatide
Drug Cost (USD) : 52,079,801
Year : 2018
Prescribers : 6480
Prescriptions : 26090
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Abaloparatide
Drug Cost (USD) : 4,903,353
Year : 2017
Prescribers : 1184
Prescriptions : 2457
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Abaloparatide
Drug Cost (USD) : 0
Year : 2016
Prescribers :
Prescriptions : 0
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Abaloparatide
Drug Cost (USD) : 0
Year : 2015
Prescribers :
Prescriptions : 0
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?